

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER UCSD1140-1
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/889251)
			INTERNATIONAL APPLICATION NO. • PCT/US00/04663

TITLE OF INVENTION
METHODS OF TREATMENT OF MITOCHONDRIAL DISORDERS

APPLICANT(S) FOR DO/EO/US
Robert K. Naviaux

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). **Unsigned**
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. A **FIRST** preliminary amendment.
16. A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. A substitute specification.
18. A change of power of attorney and/or address letter.
19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. Certificate of Mailing by Express Mail EL617043576
23. Other items or information:

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.492 (a)(1) - (5)) 09/889251	INTERNATIONAL APPLICATION NO. PCT/US00/04663	ATTORNEY'S DOCKET NUMBER UCSD1140-1
--	--	---

24. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$1000.00				
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$860.00				
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$710.00				
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$690.00				
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$100.00				
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$100.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than _____ months from the earliest claimed priority date (37 CFR 1.492 (e)).				<input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30	\$130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	27 - 20 =	7	x \$18.00	\$126.00	
Independent claims	4 - 3 =	1	x \$80.00	\$80.00	
Multiple Dependent Claims (check if applicable) <input checked="" type="checkbox"/>				\$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$706.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				\$353.00	
SUBTOTAL =				\$353.00	
Processing fee of \$130.00 for furnishing the English translation later than _____ months from the earliest claimed priority date (37 CFR 1.492 (f)).				<input type="checkbox"/> 20 <input type="checkbox"/> 30	\$0.00
TOTAL NATIONAL FEE =				\$353.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				<input type="checkbox"/>	\$0.00
TOTAL FEES ENCLOSED =				\$353.00	
				Amount to be refunded	\$
				charged	\$

- a. A check in the amount of **\$353.00** to cover the above fees is enclosed.
- b. Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **50-1355** A duplicate copy of this sheet is enclosed.
- d. Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Lisa A. Haile, Ph.D.
 Gray Cary Ware Freidenrich LLP
 4365 Executive Drive, Suite 1600
 San Diego, CA 92121

Lisa A. Haile

 SIGNATURE

Lisa A. Haile, Ph.D.

 NAME

38,347

 REGISTRATION NUMBER

July 13, 2001

 DATE


mitochondrial dysfunction in culture are known to be dependent on exogenous uridine for growth and survival because of a functional deficiency in the activity of DHO-QO.

The epidemiology of the inherited forms of mitochondrial disease is largely unknown. It has been estimated that between 1 in 4000 and 1 in 1000 live births in the U.S. will be diagnosed with a mitochondrial disease before the age of 10 years. This is roughly comparable to the incidence of childhood cancer. Degenerative disorders of aging in which mitochondria play a role are, of course, much more common, affecting as many as 20-85 million Americans. Despite the wide-ranging effects of mitochondrial disorders, there is no currently accepted treatment methodology for addressing a problem of such significance and magnitude.

Accordingly, there is still a need in the art for a method for treating mitochondrial disorders, as a class.

BRIEF DESCRIPTION OF THE INVENTION


As a result of the recognition by the inventors of the role of certain pyrimidine-based nucleosides in mitochondrial disorders, the present invention provides a unifying method for the treatment of such. Thus, in accordance with the present invention, there are provided methods for the treatment of a mitochondrial disorder. Invention methods include administering to a subject having or at risk of having such disorder an effective amount of a compound of Formula I:



(I)

wherein:

R₁ is OH, NHCOCH₃, or NH₂,
 R₂ is H, CO₂H, or



5

(II)

wherein:

10 X is C₁-C₂₂ alkyl, C₁-C₂₂ alkenyl or C₁-C₂₂ alkynyl, with substituents selected from the group consisting of H, C₁₋₃ alkyl, OH, NH₂, and halogen, or wherein X is H,

15 R₃, R₄, and R₅ are, independently, optionally substituted C₁-C₂₂ alkyl carbonyl, with substituents selected from the group consisting of C₁₋₃ alkyl, OH, NH₂, halogen, and H, wherein at least one of R₃, R₄, and R₅ is not H.

Exemplary compounds according to Formula (I) include triacetyluridine.

Accordingly, in another embodiment of the present invention there are provided
 20 methods for the treatment of a mitochondrial disorder. Invention methods include administering to a subject having or at risk of having such disorder an effective amount of 2', 3', 5'-tri-O- acetyl-1-β-D-uridine (hereinafter "triacetyluridine").

In still another embodiment of the present invention there are provided for
 25 reducing or eliminating one or more symptoms associated with a mitochondrial disorder. Invention methods include administering to a subject in need thereof an effective amount of a compound of Formula I, wherein R₁ - R₅ and X are as defined above.

Similarly, in another embodiment of the present invention, there are provided
 30 methods for reducing or eliminating one or more symptoms associated with a mitochondrial disorder including administering to a subject having or at risk of having such disorder, an effective amount of triacetyluridine.

TOTAL PAGES 60

DETAILED DESCRIPTION OF THE INVENTION


The present invention is based on the discovery that pyrimidine-based nucleosides, such as triacetyluridine and related compounds, are effective for treating mitochondrial disorders in which there is a decrease in pyrimidine biosynthesis. The methods of the present invention are an improvement upon the current most commonly used treatments of mitochondrial disorders. This is because pyrimidine-based nucleosides such as triacetyluridine supplement a patient's own production of pyrimidines as well as increasing the systemic levels of pyrimidines. This in turn serves to maintain the natural metabolic and biosynthetic processes of tissues *in vivo*, especially those tissues with high metabolic load such as in nervous, muscular and organ tissues.

The absence of one or more pyrimidine-based nucleosides has been implicated in a number of disorders which can now be broadly classified as mitochondrial disorders. All of the pyrimidine-based nucleosides (except for orotic acid) can be synthesized using uridine as a starting compound. Thus, a uridine deficiency can result in deficiencies of all other pyrimidine-based nucleosides, and a host of sequelae. As a result, merely supplementing uridine (e.g., by administration of triacetyluridine, or the like) can address a number of symptoms and disease states.

The present invention provides methods for the treatment of mitochondrial disorders by administering one or more of a pyrimidine-based nucleoside, a precursor thereof, or the like.


Organisms contemplated for treatment in accordance with the present invention include any organism with a pyrimidine biosynthetic pathway, including, but not limited to mammals, such as humans, bovine, ovine, equine, feline, canine, and the like.

As used herein, pyrimidine-based nucleosides and precursors thereof include compounds of Formula (I), as follows:



(I)

5 wherein:
 R₁ is OH, NHCOCH₃, or NH₂,
 R₂ is H, CO₂H, or



(II)

10 wherein:

X is C₁-C₂₂ alkyl, C₁-C₂₂ alkenyl or C₁-C₂₂ alkynyl, with substituents selected from the group consisting of H, C₁₋₃ alkyl, OH, NH₂, and halogen, or wherein X is H,

15

R₃, R₄, and R₅ are, independently, optionally substituted C₁-C₂₂ alkyl carbonyl, with substituents selected from the group consisting of C₁₋₃ alkyl, OH, NH₂, halogen, and H, wherein at least one of R₃, R₄, and R₅ is not H.

20

Alkyl carbonyl R groups contemplated for use in the practice of the present invention include carbonyl derivatives of amino acids (i.e., when the amino substituent is on the α carbon of the alkyl carbonyl), monocarboxylic acids, dicarboxylic acids, and the like. In one aspect of the present invention dicarboxylic acid substituents contemplated for use in the practice of the present invention have in

25

the range of about 3 to 22 carbons.

Carbonyl derivatives of amino acids contemplated for use as substituents in the practice of the present invention include carbonyl derivatives of glycine, L-forms of alanine, valine, leucine, isoleucine, tyrosine, proline, hydroxyproline, serine, threonine, cystine, cysteine, aspartic acid, glutamic acid, arginine, lysine, histidine, carnitine, ornithine, and the like.

Exemplary compounds of Formula I include triacetyluridine, tetracylcytidine, triacetyluronic acid esters, analogs thereof, and the like. In a presently preferred aspect of the invention, the pyrimidine-based nucleoside is triacetyluridine.

For simplicity, Formula I illustrates the active compounds in the naturally occurring D-configuration, but the present invention also encompasses, isomers (e.g. compounds showing keto-enol tautomersism), compounds in the L-configuration, and mixtures of compounds in the D- and L-configurations, unless otherwise specified. The naturally occurring D-configuration is presently preferred.

The compounds of the invention may be present in the form of their pharmaceutically acceptable salts, such as, but not limited to, an alkali metal salt such as sodium or potassium; an alkaline earth metal salt such as manganese, magnesium, or calcium; or an ammonium or tetraalkyl ammonium salt, i.e., NX^4+ (wherein X is C1-4). Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects.

In another embodiment of the present invention, methods for treatment of mitochondrial disorders, and methods for reducing or eliminating symptoms associated with a mitochondrial disorder, further comprise the administration of one or more vitamins and cofactors. Vitamins contemplated for use in accordance with the present invention include thiamine (B1), riboflavin (B2), niacin (B3), pyridoxine (B6), folate, cyanocobalamin (B12), biotin, pantothenic acid, and the like. Cofactors contemplated for use in accordance with the present invention include Coenzyme Q, calcium pyruvate, and the like.

Invention methods are contemplated for use in the treatment of all mitochondrial disorders, particularly those associated with a pyrimidine deficiency, and most particularly those associated with a deficiency in uridine. Specific mitochondrial disorders contemplated for treatment in accordance with the present invention include

5 MELAS (Mitochondrial encephalomyopathy with lactic acidemia and stroke-like episodes), MERRF (Myoclonus, epilepsy, and myopathy with ragged red fibers), NARP/MILS (Neurogenic muscular weakness, ataxia, retinitis pigmentosa/Maternally inherited Leigh syndrome), LHON (Lebers hereditary optic neuropathy) “Mitochondrial blindness”, KSS (Kearns-Sayre Syndrome), PMPS (Pearson Marrow-

10 Pancreas Syndrome), CPEO (Chronic progressive external ophthalmoplegia), Leigh syndrome, Alpers syndrome, Multiple mtDNA deletion syndrome, MtDNA depletion syndrome, Complex I deficiency, Complex II (SDH) deficiency, Complex III deficiency, Cytochrome c oxidase (COX, Complex IV) deficiency, Complex V deficiency, Adenine Nucleotide Translocator (ANT) deficiency, Pyruvate

15 dehydrogenase (PDH) deficiency, Ethylmalonic aciduria with lactic acidemia, 3-Methyl glutaconic aciduria with lactic acidemia, Refractory epilepsy with declines during infection, Asperger syndrome with declines during infection, Autism with declines during infection, Attention deficit hyperactivity disorder (ADHD), Cerebral palsy with declines during infection, Dyslexia with declines during infection,

20 materially inherited thrombocytopenia and leukemia syndrome, MNGIE (Mitochondrial myopathy, peripheral and autonomic neuropathy, gastrointestinal dysfunction, and epilepsy), MARIAHS syndrome (Mitochondrial ataxia, recurrent infections, aphasia, hypouricemia/hypomyelination, seizures, and dicarboxylic aciduria), ND6 dystonia, Cyclic vomiting syndrome with declines during infection, 3-

25 Hydroxy isobutyric aciduria with lactic acidemia, Diabetes mellitus with lactic acidemia, Uridine responsive neurologic syndrome (URNS), Familial Bilateral Striatal Necrosis (FBSN), Aminoglycoside-associated deafness, Dilated cardiomyopathy, Splenic Lymphoma, Wolfram syndrome, Multiple mitochondrial DNA deletion syndromes, and Renal Tubular Acidosis/Diabetes/Ataxia syndrome.

30 Another aspect of the present invention is a method of treating a mammal (e.g., human, etc.) with mitochondrial disorders arising from, but not limited to Post –

00000001 110101

traumatic head injury and cerebral edema, Stroke (invention methods useful for preventing or preventing reperfusion injury), Alzheimer's dementia, Lewy body dementia, Huntington's disease, Amyotrophic lateral sclerosis, Parkinson's disease, Hepatorenal syndrome, Acute liver failure – NASH (non-alcoholic steatohepatitis),
5 Diabetes melitus (particularly TypeII), Anti-metastasis/prodifferentiation therapy of cancer, Idiopathic congestive heart failure, Atrial fibrillation (non-valvular), Wolff-Parkinson-White Syndrome, Idiopathic heart block, Prevention of reperfusion injury in acute myocardial infarctions, Familial migraines, Irritable bowel syndrome, Secondary prevention of non-Q wave myocardial infarctions, Premenstrual syndrome, Prevention
10 of renal failure in hepatorenal syndrome, Anti-phospholipid antibody syndrome, Eclampsia/pre-eclampsia, Oopause infertility, Ischemic heart disease/Angina, and Shy-Drager and unclassified dysautonomia syndromes.

In still another embodiment, there are provided methods for the treatment of mitochondrial disorders associated with pharmacological drug-related side effects.

15 Types of pharmaceutical agents that are associated with mitochondrial disorders include reverse transcriptase inhibitors, protease inhibitors, inhibitors of DHOD, and the like. Specific reverse transcriptase inhibitors include Azidothymidine (AZT), Stavudine (D4T), Zalcitabine (ddC), Didanosine (DDI), Fluoriodoauracil (FIAU), and the like. Specific protease inhibitors include RITONAVIR™, INDINAVIR™,
20 SAQUINAVIR™, NELFINAVIR™, and the like. Specific inhibitors of dihydroorotate dehydrogenase (DHOD) include LEFLUNOMIDE™, BREQUINAR™, and the like.

Because certain symptoms of mitochondrial disorders can be associated with one or more pyrimidine-related deficiencies, in another embodiment of the present invention,
25 there are provided methods for reducing or eliminating one or more symptoms associated with a mitochondrial disorder. Symptoms associated with mitochondrial disorders include renal tubular acidosis (RTA), impaired eyesight, dementia, seizures, cardiomyopathy, skeletal myopathy, peripheral myopathy, autonomic myopathy, and the like.

Mitochondrial disorders can be classified according to their effects on certain mitochondria-specific biosynthetic pathways. Thus, in another embodiment of the present invention there are provided methods for the treatment of mitochondrial disorders that are the result of a perturbation or defect in a mitochondrial biosynthetic pathway. A primary biosynthetic pathway of the mitochondria is that for pyrimidine biosynthesis. Because invention methods comprise the administration of pyrimidines, pyrimidine analogs, precursors thereof, biosynthetic pathways contemplated for treatment by invention methods include biosynthetic pathways for pyrimidines, including uridine, thymidine, cytosine, and the like. Specific deficiencies in pyrimidine biosynthetic pathways include those associated with particular enzymes in the pathway of interest. Such deficiencies include, missing enzymes, reduced expression of enzymes, defective (e.g., mutant) enzymes having reduced or no activity, and the like. Specific enzymes include dihydroorotate dehydrogenase (DHOD), uridine monophosphate synthetase (UMPS), and the like.

The present invention further provides pharmaceutical compositions comprising a unit dosage form containing pyrimidine-based nucleosides according to Formula I, analogs thereof, and the like.

The active components described for use herein can be formulated with a pharmaceutically suitable vehicle, selected to render such compositions amenable to delivery by oral, rectal, parenteral (e.g., intravenous, intramuscular, intraarterial, intraperitoneal, and the like), or inhalation routes, osmotic pump, topical, ophthalmic, and the like.

Ointments are semi-solid preparations that consist of the active ingredient incorporated into a fatty, waxy, or synthetic base.

Examples of suitable creams include, but are not limited to, water-in-oil and oil-in-water emulsions. Water-in-oil creams may be formulated by using a suitable emulsifying agent with properties similar, but not limited, to those of the fatty alcohols such as cetyl alcohol or cetostearyl alcohol and to emulsifying wax. Oil-in-water creams may be formulated using an emulsifying agent such as cetomacrogol

emulsifying wax. Suitable properties include the ability to modify the viscosity of the emulsion and both physical and chemical stability over a wide range of pH. The water soluble or miscible cream base may contain a preservative system and may also be buffered to maintain an acceptable physiological pH.

5 In addition to the topical method of administration described above, there are various methods of administering the compounds of the present invention systemically. One such means would involve an aerosol suspension of respirable particles comprised of the active compound, which the subject inhales. The active compound would be absorbed into the bloodstream via the lungs and contact the systemic circulation in a pharmaceutically effective amount. The respirable particles may be liquid or solid, with a particle size sufficiently small to pass through the mouth and larynx upon inhalation; in general, particles ranging from about 1 to 10 microns, but more preferably 1-5 microns, in size are considered respirable.

10 Another means of systemically administering the active compounds to the subject would involve administering a liquid/liquid suspension in the form of nasal drops of a liquid formulation, or a nasal spray of respirable particles which the subject inhales. Liquid pharmaceutical compositions of the active compound for producing a nasal spray or nasal drops may be prepared by combining the active compound with a suitable vehicle, such as sterile pyrogen free water or sterile saline by techniques known to those skilled in the art.

15 Other means of systemic administration of the active compound would involve oral administration, in which pharmaceutical compositions containing compounds of Formula I, are in the form of a solid, a solution, an emulsion, a dispersion, a micelle, a liposome, and the like, wherein the resulting formulation contains the active compounds contemplated for use herein, in admixture with an organic or inorganic carrier or excipient suitable for nasal, enteral or parenteral applications. The active ingredients may be compounded, for example, with the usual non-toxic, pharmaceutically or physiologically acceptable carriers for tablets, pellets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, suppositories, solutions, emulsions, suspensions, hard or soft capsules, caplets or syrups or elixirs and any other

FOR "SECRET"

form suitable for use. The carriers that can be used include gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents may be used. The active compounds contemplated for use herein are included in the pharmaceutical formulation in an amount sufficient to produce the desired effect upon administration (i.e., a therapeutically effective amount).

The powder, solution, suspension, or tablet contains the active compound in a physiologically compatible vehicle, as those skilled in the art of oral delivery system development can select using conventional criteria. For example, such formulations may contain one or more agents selected from flavoring agents (such as peppermint, oil of wintergreen or cherry), coloring agents, preserving agents, and the like, in order to provide pharmaceutically elegant and palatable preparations. Tablets containing the active ingredients in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate, sodium phosphate, and the like; (2) granulating and disintegrating agents, such as corn starch, potato starch, alginic acid, and the like; (3) binding agents, such as gum tragacanth, corn starch, gelatin, acacia, and the like; and (4) lubricating agents, such as magnesium stearate, stearic acid, talc, and the like. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. The tablets may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874, incorporated herein by this reference, to form osmotic therapeutic tablets for controlled release.

When formulations for oral use are in the form of hard gelatin capsules, the active ingredients may be mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, kaolin, or the like. They may also be in the form of

soft gelatin capsules wherein the active ingredients are mixed with water or an oil medium, for example, peanut oil, liquid paraffin, olive oil, and the like.

Additional means of systemic administration of the active compound to the subject would involve a suppository form of the active compound, such that a
5 therapeutically effective amount of the compound reaches the systemic circulation.

The quantity of the active compound (i.e., pyrimidine-based nucleoside of Formula I) included in the pharmaceutical composition is an amount sufficient to ameliorate signs and symptoms of mitochondrial disorders in the subject of from
10 about 0.5 g/m²/day to about 20 g/m²/day, more preferably from about 2 g/m²/day to about 10 g/m²/day, and in an even more preferred embodiment, about 6 g/m²/day. As used herein, the units m² denote surface area (SA), and are determined by the following formula: SA in m² = (height in cm)^{0.75} x (weight in kg)^{0.425} x 71.84 ÷
10,000.

Depending on the solubility of the particular formulation of active compound
15 administered, the daily dose to ameliorate signs and symptoms of mitochondrial disorders may be divided among one or several unit dose administrations. The total daily dose for triacetyluridine (for example) may range from 1 to 20 grams per day, depending upon the age and state of the subject, given at a regimen of up to five times per day or on an as needed basis to address acute exacerbations.

20 Co-factors and vitamins to be optionally administered in accordance with invention are to be given at an appropriate daily dosage. Daily dosages contemplated for administration in accordance with invention methods are set out in Table I.

Table I

Coenzyme or vitamin	Range of daily dosages	Presently preferred daily dosage
Coenzyme Q	about 1 – 10 mg/kg/day	about 5 mg/kg/day
Calcium pyruvate	about 1 – 6 g/m ² /day	about 3 g/m ² /day
Thiamine (B1)	about 0.5 – 5 mg/kg/day	about 50 –200 mg/day
Riboflavin (B2)	about 0.5 – 5 mg/kg/day	about 50 –200 mg/day
Niacin	about 0.5 – 20 mg/kg/day	about 50 –200 mg/day
Pyridoxine (B6)	about 0.5 – 5 mg/kg/day	about 50 –200 mg/day
Folate	about 0.005 – 0.03 mg/kg/day	about 0.4 - 2 mg/day
Cyanocobalamine (B12)	about 0.001 – 0.03 mg/kg/day	about 0.05 – 0.5 mg/day
Biotin	about 0.005 – 0.2 mg/kg/day	about 0.05 – 0.5 mg/day
Pantothenic acid	about 0.5 – 5 mg/kg/day	about 50 – 200 mg/day

As those of skill in the art will understand, the above dosages are general in nature and can be tailored to the individual subject's needs by an appropriate treating health care professional, taking into account the subject's age, weight, size, condition, and the like.

Compounds of Formula I can be made by methods which are well known to those skilled in the art and in accordance with known procedures F.J.M. Rajabalee, *Angew. Chem. Int. Ed.*, vol. 10, p.75 (1971); some are commercially available, for example, from Sigma Chemical Company, PO Box 14508, St. Louis, MO 63178.

The invention will now be described in greater detail by reference to the following non-limiting examples.

Angew. Chem. Int. Ed., vol. 10, p.75 (1971); some are commercially available, for example, from Sigma Chemical Company, PO Box 14508, St. Louis, MO 63178.

The invention will now be described in greater detail by reference to the following non-limiting examples.

5

EXAMPLES

Example 1 - Treatment of mitochondrial disease with triacetyl uridine

Patients. Four patients with mitochondrial renal tubular acidosis (RTA) were studied. Mitochondrial RTAs often defy simple classification as proximal (type II) or distal (type I) tubulopathies, as these patients are often mosaics and express features of both phenotypes leading to hyperchloremic (non-anion gap) metabolic acidoses.

Patient #1 was a 2 year old female with Leigh syndrome, lactic acidemia, and complex I deficiency who required 200 mEq/day of NaHCO_3 to compensate for renal losses of alkali, and maintain serum bicarbonate levels above 20 mEq/l, 1+ proteinuria, and significant aminoaciduria with hydroxyprolinuria.

Patient #2 was a 3 year old female with Leigh syndrome, and complex IV (COX) deficiency, who also required 200 mEq/day of NaHCO_3 .

Patient #3 was a 2 year old male with Leigh syndrome, lactic acidemia, 1+ proteinuria, and pyruvate dehydrogenase (PDH) deficiency, who required up to 210 mEq/day of NaHCO_3 .

Patient #4 was an 11 year old male with 3-hydroxyisobutyric aciduria, lactic acidemia, and encephalomyopathy, who required 468 mEq/day of NaHCO_3 .

Methods. Blood and urine electrolytes, creatinine, pH, urinalysis, and venous blood gases were studied before and after treatment. Quantitative urine amino acids and organic acids were also obtained. Pre-enrollment doses of oral sodium bicarbonate were continued for the first 3 days of triacetyluridine treatment, then reduced weekly as tolerated to maintain serum bicarbonate above 20 mEq/l.

Treatment. Patients received triacetyluridine 2 g/m² PO TID.

Results. Patient #1 experienced complete correction of her RTA within 24 hours of treatment, maintaining a serum bicarbonate of more than 20 mEq/l without any further oral bicarbonate. She also had complete resolution of her

5 hydroxyprolinuria within 2 weeks.

Urinary bicarbonate losses in patient #2 were initially 99 mEq/l. The fractional excretion of bicarbonate (FE_{HCO₃}) was 9.3% prior to therapy. After 36 hours on treatment with triacetyluridine, urinary bicarbonate losses were undetectable (<5 mEq/l). After 3 weeks of treatment, just 25% of the patient's pre-enrollment dose

10 of bicarbonate was needed to maintain normal serum bicarbonate.

Urinary bicarbonate losses in patient #3 were 59 mEq/l. The FE_{HCO₃} was 10.0% prior to therapy. After 36 hours of treatment with triacetyluridine, urinary bicarbonate losses were undetectable (<5 mEq/l). After 3 weeks of treatment the patient required just 10% of his previous dose of bicarbonate.

15 Following 1 week of treatment, patient #4 had a 35% reduction in his oral bicarbonate requirement. Treatment is continuing.

Conclusion. Renal tubular acidosis was corrected or dramatically improved in 4 out of 4 patients with mitochondrial disease treated with triacetyluridine.

Example 2 – Treatment by administration of triacetyluridine to a subject

20 *having MARIAHS syndrome*

Patient. CMZ is a child with mitochondrial ataxia, recurrent infections, aphasia, hypouricemia/ hypomyelination, and seizures (MARIAHS syndrome), cared for since 1 year of age. Symptoms indicate a primary deficiency in the enzyme dihydoroate dehydrogenase, the rate-limiting step in *de novo* pyrimidine synthesis,

25 which could lead to a functional dependence on exogenous uridine.

Treatment. At 3 years of age treatment began with uridine. At 4.5 yrs the treating agent was switched to triacetyluridine because it is a more easily absorbed form of uridine.

Results. CMZ has flourished. Her seizures have decreased from twice a
5 month to once every 2 months. Motor and language development have markedly improved. She is learning her alphabet, knows her colors, and has begun using two word sentences. Mild truncal ataxia persists. A follow-up brain MRI after 20 months on uridine showed no progression in her white matter disease. There has been no biochemical, hematologic, or clinical toxicity, although one additional seizure was
10 noted within 10 days of starting triacetyluridine. The initial triacetyluridine dose was 0.1 g/kg/day. Within 2 months of a dose increase to 0.2 g/kg/day there was a rapid increase in expressive language acquisition and a narrowing of her previous broad-based, ataxic gait. She has recently been increased to 0.3 g/kg/day and has begun 0.75 g of calcium pyruvate TID.

Conclusion. Treatment of MARIAHS syndrome by administration of
15 triacetyluridine results in a dramatic improvement in the patient's condition, and a marked reduction in symptomatology.

Example 3 – Treatment by administration of triacetyluridine to a subject having a variety of symptoms and a familial history of mitochondrial disease

Patient. KL is an adult who first came to the investigator's attention after the
20 diagnosis of her son with mitochondrial disease leading to stroke-like episodes, ataxia, and encephalopathy. Before administration of triacetyluridine, KL suffered with recurrent pyelonephritis, infection-association neutropenia, hemiplegic/aphasic migraines, grand-mal seizures, neurogenic bowel and bladder requiring QID
25 catheterization, biliary dyssynergia, dysphagia and pc cough, peripheral and autonomic polyneuropathy, painful paresthesias, cardiac conduction disturbances with SVT and tachy-brady syndrome, severe orthostatic hypotension, orthopnea, and poor functional capacity with inability to climb a flight of stairs without stopping to rest,

succeeding 4 months. He was having 8-10 grand-mal seizures every night, leaving him postictal for much of the morning. He also developed upper lip automaticity.

Treatment. The patient was initially administered 0.05 g/kg/day of triacetylrudine for one week, followed by 0.16 g/kg/day for 1 week, and then 0.24
5 g/kg/day.

Results. His seizures and involuntary lip movements stopped completely in the first three days of emergence of his upper lip automaticity. Because his tegretol was found to be subtherapeutic (it was 4 µg/ml both before and after starting triacetylrudine), his tegretol dose was increased, with the aim of achieving
10 therapeutic levels of 8-12 µg/ml, and his triacetylrudine was increased to 0.16 g/kg/day. After three weeks, his dose of triacetylrudine was increased to 0.24 g/kg/d and 0.5 g calcium pyruvate TID was added. This resulted in a transient escalation in his nocturnal seizure activity, which after 3 days, decreased to zero. For several weeks, SF was able to return to school and play little league baseball again.

15 *Example 5 – Treatment by administration of triacetylrudine to a subject having Leigh syndrome*

Patient. CS was a 2 year old girl with Leigh syndrome, lactic acidemia, and renal tubular acidosis who suffered a hypertensive crisis and acute edema as she came out of general anesthesia for replacement of an elective percutaneous gastrostomy
20 tube (PEG). The gastrostomy tube was needed only because her daily bicarbonate requirements were so great (25 mEq/kg/day), that she could not meet her needs without a tube in her stomach to introduce the bicarbonate. She developed pneumonia as a complication of PEG and developed new Leigh syndrome lesions in the spinal cord, midbrain, and thalamus. She drifted into a coma 3 days after PEG placement.

25 **Treatment.** CS received emergency treatment with triacetylrudine.

Results. The patient's renal tubular acidosis completely resolved within 12 hours of starting triacetylrudine. She did not require any further supplemental bicarbonate, her aminoaciduria improved, and plasma amino acids returned to normal


ranges within 2 hours of triacetyluridine, while receiving continuous parenteral nutrition. Despite a favorable biochemical response, she never awoke from her coma, and died after a 4 week terminal illness.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

0939251 40101
"TPT" 526660

WHAT IS CLAIMED IS:

1. A method for the treatment of a mitochondrial disorder comprising administering to a subject having or at risk of having such disorder an effective amount of a compound of Formula I:




(I)

wherein:

R₁ is OH, NHCOCH₃, or NH₂,

R₂ is H, CO₂H, or



(I)

wherein:

X is C₁-C₂₂ alkyl, C₁-C₂₂ alkenyl or C₁-C₂₂ alkynyl, with substituents selected from the group consisting of H, C₁₋₃ alkyl, OH, NH₂, and halogen, or wherein X is H,

R₃, R₄, and R₅ are, independently, optionally substituted C₁-C₂₂ alkyl carbonyl, with substituents selected from the group consisting of C₁₋₃ alkyl, OH, NH₂, halogen, and H, wherein at least one of R₃, R₄, and R₅ is not H,

thereby treating the disorder.


2. A method for the treatment of a mitochondrial disorder comprising administering to a subject having or at risk of having such disorder, an effective amount of 2', 3', 5'-tri-O- acetyl-1-β-D-uridine.

3. A method according to claim 1 or claim 2, wherein the optionally substituted alkyl carbonyl is unbranched and has in the range of about 5 to 22 carbons.
4. A method according to claim 1, wherein the alkyl carbonyl is a carbonyl derivative of an amino acid selected from the group consisting of glycine, L-forms of alanine, valine, leucine, isoleucine, tyrosine, proline, hydroxyproline, serine, threonine, cystine, cysteine, aspartic acid, glutamic acid, arginine, lysine, histidine, carnitine, and ornithine.
5. A method according to claim 1, wherein the alkyl carbonyl is a carbonyl derivative of a dicarboxylic acid having in the range of about 3 to 22 carbons.
6. A method according to claim 1, wherein the mitochondrial disorder comprises a mutation in mitochondrial or nuclear DNA.
7. A method according to claim 1 or claim 2, wherein the mitochondrial disorder is selected from the group consisting of:
 - Huntington's disease,
 - Amyotrophic lateral sclerosis,
 - MELAS (Mitochondrial encephalomyopathy with lactic acidemia and stroke-like episodes),
 - MERRF (Myoclonus, epilepsy, and myopathy with ragged red fibers),
 - NARP/MILS (Neurogenic muscular weakness, ataxia, retinitis pigmentosa/Maternally inherited Leigh syndrome),
 - LHON (Lebers hereditary optic neuropathy) "Mitochondrial blindness",
 - KSS (Kearns-Sayre Syndrome),
 - PMPS (Pearson Marrow-Pancreas Syndrome),
 - CPEO (Chronic progressive external ophthalmoplegia),
 - Leigh syndrome,
 - Alpers syndrome,
 - Multiple mtDNA deletion syndrome,
 - MtDNA depletion syndrome,
 - Complex I deficiency,
 - Complex II (SDH) deficiency,

Complex III deficiency, Cytochrome c oxidase (COX, Complex IV) deficiency, Complex V deficiency,
 Adenine Nucleotide Translocator (ANT) deficiency,
 Pyruvate dehydrogenase (PDH) deficiency,
 Ethylmalonic aciduria with lactic acidemia,
 3-Methyl glutaconic aciduria with lactic acidemia,
 Refractory epilepsy with declines during infection,
 Asperger syndrome with declines during infection,
 Autism with declines during infection,
 Attention deficit hyperactivity disorder (ADHD),
 Cerebral palsy with declines during infection,
 Dyslexia with declines during infection, maternally inherited thrombocytopenia and leukemia syndrome,
 MNGIE (Mitochondrial myopathy, peripheral and autonomic neuropathy, gastrointestinal dysfunction, and epilepsy),
 MARIAHS syndrome (Mitochondrial ataxia, recurrent infections, aphasia, hypouricemia/hypomyelination, seizures, and dicarboxylic aciduria),
 ND6 dystonia,
 Cyclic vomiting syndrome with declines during infection,
 3-Hydroxy isobutyric aciduria with lactic acidemia,
 Diabetes mellitus with lactic acidemia,
 Uridine responsive neurologic syndrome (URNS),
 Familial Bilateral Striatal Necrosis (FBSN),
 Aminoglycoside-associated deafness,
 Dilated cardiomyopathy,
 Splenic Lymphoma,
 Wolfram syndrome,
 Multiple mitochondrial DNA deletion syndromes, and
 Renal Tubular Acidosis/Diabetes/Ataxia syndrome.

8. A method according to claim 1 or claim 2, wherein the mitochondrial disorder is a deficiency of cardiolipin.
9. A method according to claim 1 or claim 2, wherein the mitochondrial disorder comprises a deficiency in a pyrimidine synthetic pathway.

21. A method according to claim 19, wherein the vitamin is selected from the group consisting of thiamine (B1), riboflavin (B2), niacin (B3), pyridoxine (B6), folate, cyanocobalamine (B12), biotin, and pantothenic acid.
22. A method according to claim 1, wherein the compound of Formula (I) is administered in a daily dosage in the range of about 0.5 g/m² to 20 g/m².
23. A method according to claim 1, wherein the compound of Formula (I) is administered in a daily dosage in the range of about 2 g/m² to 10 g/m².
24. A method according to claim 1, wherein the compound of Formula (I) is administered in a daily dosage of about 6.0 g/m².
25. A method for reducing or eliminating one or more symptoms associated with a mitochondrial disorder comprising administering to a subject in need thereof an effective amount of a compound of Formula I:




(I)

wherein:

R₁ is OH, NHCOCH₃, or NH₂,

R₂ is H, CO₂H, or



(I)

wherein:

TOTAL 1526550

X is C₁-C₂₂ alkyl, C₁-C₂₂ alkenyl or C₁-C₂₂ alkynyl, with substituents selected from the group consisting of H, C₁₋₃ alkyl, OH, NH₂, and halogen, or wherein X is H,

R₃, R₄, and R₅ are, independently, optionally substituted C₁-C₂₂ alkyl carbonyl, with substituents selected from the group consisting of C₁₋₃ alkyl, OH, NH₂, halogen, and H, wherein at least one of R₃, R₄, and R₅ is not H,

thereby treating the disorder.

26. A method for reducing or eliminating one or more symptoms associated with a mitochondrial disorder comprising administering to a subject having or at risk of having such disorder, an effective amount of triacetyluridine.
27. A method according to claim 25 and claim 26, wherein the symptoms are renal tubular acidosis (RTA), impaired eyesight, dementia, seizures, cardiomyopathy, skeletal myopathy, peripheral myopathy or autonomic myopathy.

DECLARATION FOR PATENT APPLICATION

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship is as stated below next to my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled METHODS OF TREATMENT OF MITOCHONDRIAL DISORDERS, the specification of which

_____ is attached hereto.
X was filed on July 13, 2001 (Attorney Docket No. UCSD1140-1)
as U.S. Application Serial No. 09/889,251
and was amended on _____
if applicable (the "Application").

I hereby authorize and request insertion of the application serial number of the Application when officially known.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

With respect to the Application, I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/121,588 February 23, 1999
(Application Serial No.) (Filing Date)

FOR FILING

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

COUNTRY	APPLICATION NO.	FILING DATE	PRIORITY CLAIMED	
<u>US</u>	<u>PCT/US00/04663</u>	<u>February 23, 2000</u>	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00
Full name of first inventor: Robert K. Naviaux

Inventor's signature: R. K. Naviaux

Date: 9/28/01

Residence: 11760 Calamar Drive, San Diego, California USA CA

Citizenship: USA

Post Office Address: 11760 Calamar Drive, San Diego, California USA

09889551 1001

Rec'd PCT/PTO 01 NOV 2001

GRAYCARY. TECHNOLOGY'S LEADING EDGE #3
097889251

4365 Executive Drive, Suite 1600
San Diego, CA 92121-2189
www.graycary.com

O] 858-677-1456
F] 858-677-1465

PATENT
ATTORNEY DOCKET NO. UCSD1140-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert K. Naviaux Art Unit: Unassigned
Serial No.: Examiner Unassigned
Filed: July 13, 2001
Title: METHODS OF TREATMENT OF MITOCHONDRIAL DISORDERS

Commissioner for Patents
Washington, D.C. 20231

POWER OF ATTORNEY BY ASSIGNEE

As a below-named assignee of the above-identified application ("Application"):

I hereby appoint the following attorneys of the assignee to prosecute the Application and to transact all business in the United States Patent and Trademark Office connected therewith:

Customer Number 28213

I hereby authorize and request insertion of the application number of the Application when officially known.

Direct all telephone calls to:

LISA A. HAILE, PH.D.
Telephone: (858) 677-1456


FOR FILING

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
UCSD1140-1
Page Two

Address all correspondence to:

LISA A. HAILE, PH.D.
GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, CA 92121

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
a University of the State of California

By: 

Name: Dr. Alan Paau

Title: Director, UCSD Technology Transfer

Date: 9/17/01

FOR FILING

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert K. Naviaux
Serial No.: Unassigned
Filed: July 13, 2001
Title: METHOD AND TREATMENT OF MITOCHONDRIAL DISORDERS

Commissioner for Patents
Washington, D.C. 20231

DECLARATION OF MAILING BY "EXPRESS MAIL"

I Mikhail Bayley declares as follows:

1. I reside at 4551 W. TAINWADGE DR and am an employee of Gray Cary Ware & Freidenrich LLP, 4365 Executive Drive, Suite 1600, San Diego, CA 92121-2189.

2. On 07/13/2001, I deposited in the mail, "Express Mail Post Office to Addressee" service of the United States Postal Service the contents of the envelope for which "Express Mail" receipt No. **EL617043576US** was addressed to: Commissioner of Patents, Washington, D.C. 20231.

3. Attached hereto is a true copy of the "Express Mail" receipt no. **EL617043576US**.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the above-identified application or any patents issued thereon.

Date: 07/13/2001

Mikhail Bayley

098999991 10101